, /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the treatment of advanced breast cancer.
HER3 is broadly expressed across various solid tumors, including breast, ovarian, colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients globally. While traditional HER3-targeted ADCs have demonstrated therapeutic potential in combination settings, their clinical utility has historically been constrained by dose-limiting toxicities.
AK138D1 is a next-generation, differentiated HER3-targeting ADC developed in-house by Akeso. Leveraging a unique, innovative design, AK138D1 is engineered to reduce uptake in normal tissues, thereby minimizing off-target toxicities and widening the therapeutic window. Furthermore, its design prevents the clustering of ADC molecules on the tumor surface, enhancing deep tissue penetration and uniform distribution to overcome the "binding site barrier". Early-stage clinical studies conducted in China and Australia have demonstrated that AK138D1 exhibits robust anti-tumor activity in solid tumors and breast cancer, coupled with an excellent safety profile, notably characterized by low hematologic toxicity and the absence of interstitial lung disease (ILD). This compelling balance of efficacy and safety overcomes common limitations of conventional ADCs, establishing a foundation for AK138D1 to be explored in diverse combination therapeutic regimens.
The AK138D1-202 study focuses on the two major breast cancer subtypes with the greatest unmet need: hormone receptor-positive, HER2-negative (HR+/HER2-) disease, which accounts for approximately 65% of all breast cancers, and triple-negative breast cancer (TNBC), which represents 10-20% of cases. The trial enrolls patients across multiple treatment lines from treatment-naïve to heavily pretreated, and includes diverse PD-L1 expression levels. Breast cancer remains the most common cancer among women worldwide, with an estimated 2.3 million new cases diagnosed annually. Substantial unmet needs persist in both first-line and later-line settings for HR+/HER2- breast cancer and TNBC.
Early data from AK138D1 studies have already shown meaningful efficacy and a strong safety profile in breast cancer. Concurrently, a Phase III study of ivonescimab-based combination therapy in first-line TNBC is ongoing. The combination of AK138D1 and ivonescimab is poised to emerge as a highly differentiated "IO2.0 + ADC2.0" therapeutic strategy for advanced breast cancer.
As IO+ADC combinations become a cornerstone of global oncology research, Akeso is strategically and efficiently building a comprehensive global portfolio of these next-generation therapies, leveraging its proprietary leadership in bispecific and multispecific antibody platforms.
On the IO front, Akeso stands as the only company globally with two approved bispecific antibodies for oncology, spearheading the advancement of IO2.0 therapies. Regarding its ADC pipeline, Akeso's development of AK146D1 (a Trop2/Nectin4 bispecific ADC) and AK138D1, among other innovations, aims to resolve the toxicity-related limitations of current ADCs and propel the field into the "ADC2.0" era.
About AK138D1
Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the topoisomerase I inhibitor DXd through a cleavable linker, MC-AAA (maleimide-alanine-alanine-alanine). After binding to HER3 on tumor cells, the ADC is internalized into the tumor cells, where the linker is cleaved, releasing the membrane-permeable DXd. This leads to DNA damage and subsequent cell apoptosis. Early study results have shown that AK138D1 possesses potent biological activity and a favorable safety profile. A phase II clinical trial is currently ongoing to investigate AK138D1 combined with cadonilimab and ivonescimab in patients with solid tumors. This regimen is a critical part of Akeso's IO2.0 + ADC 2.0 combination approach.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.
Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Willis, a WTW business (NASDAQ: WTW), today unveiled a new version of its Climate Diagnostic model to help risk managers better understand and respond to climate-driven volatility affecting property insurance markets.
Embedded within WTW’s Risk IQ platform, Climate Diagnostic is a climate risk technology capable of predicting the current and future impact of floods, windstorms and other material climate threats on an organisation’s assets, business activities and supply chain.
As extreme weather events become more severe and frequent, insurers worldwide are responding either by increasing the cost of property insurance or withdrawing from vulnerable regions entirely. With the costs of protection predicted to keep rising with climate risks and in some regions become increasingly unsustainable, the implications for individuals, businesses and economies will be long-lasting.
In order to help address this growing protection gap, Willis has embedded Climate Diagnostic into its broking workflows and risk engineering surveys. The enhanced analytics tool enables brokers and risk managers to identify and quantify the impact of acute climate hazards, such as extreme flooding or windstorm risk, on global assets and business interruption under the current and future climates.
Peter Carter, Head of Climate Practice at Willis, said: “The volatility and frequency of climate hazards are increasing. Embedding Climate Diagnostic in broking workflows and engineering surveys sets a new industry standard, with clients benefiting from a built-in scan of the risk against ongoing climate change volatility.”
Climate Diagnostic conducts scenario-based assessments across an organisation’s portfolio to identify current and future physical risk exposure to insurable climate-related perils, stress testing risk management and finance strategies in the short, medium and longer term. With this forward-looking approach, risk managers can incorporate safety measures into their risk transfer strategies that allow for rising climate volatility and explore alternative risk management methods, such as physical adaptation or alternative risk transfer solutions.
Climate Diagnostic also estimates the value of a portfolio exposed to levels of extreme weather risk and longer-term shifts in climate patterns. This supports the stress testing of current risk financing and risk transfer strategies amidst increasing climate volatility.
Peter Carter said: “Early sighting of assets exposed to climate-related perils gives risk managers the chance to build resilience, improving future insurability before disaster strikes.”
Key features of Climate Diagnostic include:
Interactive climatic and exposure maps to view highest risk areas - or physical asset portfolio exposures - for a selection of climate risks for given climate scenarios and time horizons, locate individual assets and identify financial exposure to each hazard.It is designed to be embedded in property broking and engineering workflows, helping clients consider climate volatility in risk management decisions.Climate Diagnostic data is scientifically sound, providing an independent forward-looking lens of insurable perils to clients. About WTW
At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organisations sharpen their strategy, enhance organisational resilience, motivate their workforce and maximise performance.
Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success - and provide perspective that moves you.
Learn more at wtwco.com.
Media contact
Andrew Collis, +44 (0) 7932 725267 | [email protected]
Investment of more than €10 million will create up to 150 jobs and anchor MARSS headquarters in Nice
PARIS & CANBERRA, Australia--(BUSINESS WIRE)--Electro Optic Systems (EOS) (ASX: EOS) today confirmed an investment of more than €10 million to establish France as its European hub for AI-enabled counter-drone command and control (“C2”) systems.
"Establishing our European hub in France allows us to deliver counter-drone and command-and-control capability that partner nations own, produce, and sustain on their own terms."
Share The hub will be anchored by the headquarters of MARSS, the AI-enabled command-and-control specialist recently acquired by EOS, and will be located in Nice. The investment is expected to create up to 150 jobs over three years, including high value-added engineering and software development roles.
The new hub will strengthen France’s defence industrial ecosystem through sovereign technologies and build on EOS’s existing cooperation with KNDS. EOS will also explore the production of high-energy laser systems and the development of space domain capabilities for France and the wider European market.
“France is making a decisive commitment to its defence sovereignty, and EOS is proud to support that ambition,” said Dr. Andreas Schwer, Chief Executive Officer of EOS. “Establishing our European hub in France allows us to deliver counter-drone and command-and-control capability that partner nations own, produce, and sustain on their own terms. This is what genuine industrial sovereignty looks like.”
The announcement comes as European governments accelerate investment in air defence in response to the rapid proliferation of low-cost drones. EOS is one of a few specialised companies outside the United States able to offer high-energy laser weapons, and its model is built around full technology transfer and local production, allowing partner nations to manufacture and maintain capability without dependency on foreign export controls.
The France hub reinforces EOS’s growing European presence. The company has secured the first export order for a 100kW-class laser weapon system from the Netherlands, and has held advanced discussions with Germany following a visit by the German Federal Minister of Defence to EOS facilities.
EOS will exhibit at Eurosatory in Paris from 15 to 19 June 2026 in Hall 5A, Stand H335. Visitors can meet the team and experience live demonstrations of EOS’ AI-enabled command and control capability alongside displays of its kinetic and high-energy laser technologies.
ABOUT ELECTRO OPTIC SYSTEMS (ASX: EOS; OTC: EOPSY)
EOS operates in two divisions – Defence Systems and Space Systems:
EOS Defence Systems specialises in technology for weapon systems optimisation and integration, as well as ISR (Intelligence, Surveillance and Reconnaissance) and C4 systems for land warfare. Its key products offered include next-generation remote weapon systems, vehicle turrets, high-energy laser weapons (directed energy), as well as fully integrated and modular counter-UAS and C2 and C4 systems. C2 Systems include Command and Control Systems such as MARSS’ software-led counter-drone and critical infrastructure protection capabilities, centred on the NiDAR platform. EOS Space Systems Space Systems specialises in applying EOS-developed optical sensors and effectors to detect, track and characterise objects in space. It includes capabilities in the domain of space control. Website: https://www.eos-aus.com/
About MARSS: An EOS Company
MARSS is a global defence technology leader specialising in counter-drone and AI-powered security and surveillance systems through NiDAR. With extensive experience spanning 20 years, including research collaboration with the EU, NATO, defence agencies, academia and industry, and installations covering the globe, MARSS is a pioneer in AI-enhanced C2 and C4i solutions.
Leveraging innovation and technology to provide the highest level of security against emerging threats, MARSS’ intuitive solutions employ integrated sensor surveillance, machine learning and open-source intelligence to protect nations, critical infrastructure, naval assets, special forces, heads of state, commercial shipping and millions of lives worldwide.
About NiDAR
NiDAR is MARSS’s AI-powered Command and Control (C2) platform, providing 360-degree situational awareness across air, surface, sub-surface and land domains. The system autonomously detects, tracks, classifies and recommends responses to asymmetric threats, integrating seamlessly with a wide range of sensors and effectors to deliver end-to-end protective solutions. With more than 60 deployments worldwide, NiDAR protects what matters most: people, critical infrastructure and assets.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Commvault Systems, Inc. ("Commvault" or "the Company") (NASDAQ: CVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between April 29, 2025 and January 26, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 17, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Commvault shared overwhelmingly positive statements about its ARR growth while knowing or recklessly disregarding the fact that its growth guidance failed to factor in important variables including the type of sale. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Commvault, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SummaryBank of Hawaii offers two preferred share series with distinct yield and risk profiles, favoring Series A over Series B.BOH.PR.A trades at a significant discount to par, offers a ~6.9% yield, and benefits from strong dividend coverage and potential capital appreciation.BOH.PR.B, despite a higher coupon (~8%), trades above par, faces negative convexity, and offers an inferior yield-to-call (~6.78%), slightly less than Series A's current yield.Given current interest rate dynamics and call risk, Series A preferreds present superior risk-reward for allocating to BOH preferred stock.The Series A is rated as a buy at present, possessing both standalone and relative appeal.Tom Werner/DigitalVision via Getty Images
Bank of Hawaii (BOH) preferred shares possess an attractive yield at present. The company has two issues outstanding at present, with materially different economic profiles and underlying characteristics. The older series, BOH.PR.A was
290 Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Readers are advised to fact-check thoroughly before making any investment-related decisions; this reflects the personal views of the author and should not be pursued as formal financial or investment advice in any manner. While every effort has been made to ensure accuracy, errors may exist in the data and financial projections presented. The author is not responsible for any financial gains or losses incurred from investments made based on this content.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Property and casualty (P&C) insurer Progressive (PGR +0.32%) continued to knock it out of the park in the first quarter. So, then, why has it underperformed other insurance stocks? For instance, while Progressive shares are down over 23% in the last 12 months, Allstate shares are up nearly 12%.
While revenue and earnings growth has continued, it has slowed in recent quarters. There are also lingering concerns that a softening insurance market with increased competition, relaxed underwriting standards, and lower premiums, will eventually affect quarterly results.
Image source: Getty Images.
Diving deep into Progressive's Q1 2026 results For the first quarter, Progressive reported total revenue of $22.2 billion and net income of $2.8 billion, or around $4.81 per share. Underwriting margins came in at 13.6% . The company's combined ratio, which represents the percentage of premiums spent on claims and underwriting expenses, was 86.4. For comparison, most P&C insurers have combined ratios exceeding 90.
Today's Change
(
0.32
%) $
0.65
Current Price
$
202.91
Progressive managed to deliver strong margins while continuing to grow its total number of policies in force. Over the past year, policies in force increased 9%, from 36.3 million to 39.6 million.
Yet while Progressive's underwriting margins and growth remained industry-leading, the market had a mixed at best reaction to the latest figures. Metrics like net income and total policies in force fell slightly short of forecasts.
Premium and policyholder growth also slowed down in the quarter. Progressive reported a 6% year-over-year increase in premiums written, and an 8% increased in earned premiums. During the full year 2025, these figures were at 12% and 10%, respectively.
Shares remain pricey, despite continued uncertainty Progressive is about a month away from releasing quarterly results again, but as the company also issues monthly financial reports, investors aren't completely in the dark. On May 20, Progressive released its April 2026 financial report.
In April, Progressive once again reported solid net written and earned premium growth, with these metrics rising 6% and 7%, respectively, year-over-year. Net income also increased by 10% compared to the prior year's month. However, a large increase in realized investment gains skewed results; while Progressive's profitability increased by double digits, the company's combined ratio for the month came in at 90.2, meaning underwriting margins were only 9.8%, a big decline from reported margins during Q1 2026.
As Progressive did not provide any commentary alongside these figures, the root cause of this margin drop is unclear. We do know, based on commentary from CEO Tricia Griffith in the Q1 earnings call, that Progressive appears focused on capitalizing on a softening, more competitive insurance market to "continue on our growth trajectory."
With Griffith's comments suggesting a preference for growth over margins, it makes sense sell-side earnings forecasts remain downbeat, calling for earnings of $16.40 and $16.19 per share in 2026 and 2027, respectively. Compare that to 2025, when Progressive reported earnings of $18.25 per share . As uncertainty persists, you may want to stick to the sidelines. Progressive, trading for 12 times forward earnings, continues to trade at a premium to peers like Allstate, which trades for around 9 times earnings. That's not to say it will become one of the most undervalued stocks, but a further de-rating could be in store.
PARIS--(BUSINESS WIRE)--Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Graphic Packaging Holding Company ("Graphic Packaging" or "the Company") (NYSE: GPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 4, 2025 and February 2, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 6, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Graphic Packaging suffered from inventory management problems, increased costs and reduced demand. The Company downplayed the severity of these issues despite the fact they would have a material impact on its financial performance. The Company overstated the strength of its business model. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Graphic Packaging, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Graphic Packaging Holding Company ("Graphic Packaging" or "the Company") (NYSE: GPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of GPK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 4, 2025 to February 2, 2026
DEADLINE: July 6, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Graphic Packaging downplayed the severity of reduced demand, higher costs, and inventory management struggles. Based on these facts, Graphic Packaging's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SPSC over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Calix, Inc. ("Calix" or "the Company") (NYSE: CALX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between January 28, 2026 and April 21, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 27, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Calix's Q1 margins benefited from the advanced purchasing of memory components. The Company's supply of these memory components was rapidly decreasing due to these advanced orders. The Company's margin faced negative pressure based on the purchase of memory at increasing market prices. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Calix, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Calix, Inc. ("Calix" or "the Company") (NYSE: CALX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CALX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: January 28, 2026 to April 21, 2026
DEADLINE: July 27, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Calix's Q1 performance was improved by the advanced purchase of memory modules. As the Company's supply of memory fell, it suffered from significant margin pressure due to increasing memory prices on the open market. Based on these facts, Calix's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FS KKR Capital Corp. ("FSK" or "the Company") (NYSE: FSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 8, 2024 and February 25, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 3, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. FSK misled investors about the effectiveness of its portfolio restructuring activities. The Company overvalued its portfolio and overstated its portfolio valuation process. The Company overstated the strength of its quarterly dividend program. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about FSK, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against FS KKR Capital Corp. ("FSK" or "the Company") (NYSE: FSK) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of FSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: May 8, 2024 to February 25, 2026
DEADLINE: July 3, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. FSK overvalued its portfolio and misled the market about its portfolio valuation process. The Company downplayed weakness in its quarterly dividend program. Based on these facts, FSK's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Apollo Global presents a unique asset management and insurance model, blending traditional and innovative approaches for diversified growth. I see valuation as attractive given the company's differentiated business structure and potential for scalable returns. Key risks include execution challenges and insurance-specific headwinds that could impact Apollo's growth trajectory.
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long SpaceX ETF (Cboe: SPCU). SPCU begins trading today at 4am ET and seeks daily investment results, before fees and expenses, equal to 200% of the daily performance of SpaceX Class A common stock (NASDAQ: SPCX).
SpaceX priced its initial public offering at $135 per share and began trading on the Nasdaq on Friday, June 12, under the ticker SPCX. At that price, the company was valued at approximately $1.77 trillion, which according to reports ranks as the largest U.S. IPO in history by debut market value.
SPCU is purpose-built for active traders seeking magnified, short-term exposure to SpaceX. The Fund obtains its exposure primarily through swap agreements and/or listed options contracts rather than by holding SpaceX shares directly, allowing traders to express a high-conviction, tactical view on SpaceX in a single exchange-listed ticker, without a margin account and without managing options positions.
SPCU joins the Defiance Daily 2X Space ETF (Cboe: SPCL), which established 2X daily leveraged exposure to SpaceX on SpaceX's IPO date. On that date, SPCL's leveraged exposure was tied exclusively to SpaceX, although the Fund will hold other investments in accordance with its investment strategy and prospectus disclosures. SPCU further expands Defiance's lineup of leveraged products linked to SpaceX.
For full fund details, the prospectus, holdings, and performance current to the most recent month-end, visit defianceetfs.com/spcu or call 833.333.9383.
The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage, and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. The Fund pursues daily leveraged investment objectives, which means it is riskier than alternatives that do not use leverage. The Fund magnifies the performance of Space Exploration Technologies Corp. (the “Underlying Security”) and is designed strictly for short-term use. For periods longer than a single day, the Fund’s performance will be the result of compounded daily returns, which is very likely to differ from 200% of the return of SpaceX over the same period. It is possible that investors could lose their entire principal within a single trading day.
An investment in the Fund is not a direct investment in SpaceX.
About Defiance ETFs
Founded in 2018, Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. Our first-mover leveraged single-stock ETFs empower investors to take amplified positions in high-growth companies, providing precise leverage exposure without the need to open a margin account.
Defiance ETFs LLC is the ETF sponsor. The Fund’s investment adviser is Tidal Investments, LLC (“Tidal” or the “Adviser”).
The Fund’s investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read the prospectus and/or summary prospectus carefully before investing. Hard copies can be requested by calling 833.333.9383.
Investing involves risk. Principal loss is possible. As an ETF, the Fund may trade at a premium or discount to its net asset value (“NAV”). Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions and bid-ask spreads will reduce returns. A portfolio concentrated in a single theme or industry may be subject to a higher degree of risk. There is no guarantee the Fund’s strategy will be successful, and an investor may lose some or all of their investment.
Leveraged Investment Risk. The Fund seeks daily investment results that correspond to two times (2X) the performance of its underlying portfolio. The use of leverage magnifies both gains and losses. As a result, the Fund may experience significant losses over short periods of time, including the potential loss of the entire investment within a single trading day. If the Target Portfolio’s market value decreases by more than 50% on a given trading day, the Fund’s investors could lose all of their money. The Fund may also be subject to the following risks:
Daily Reset and Compounding Risk. The Fund is designed to achieve its stated investment objective on a daily basis. Due to the effects of compounding, the Fund’s returns over periods longer than one trading day will likely differ, and may differ significantly, from 200% of the performance of its underlying portfolio for the same period. This effect is more pronounced in volatile markets.
Short-Term Trading Risk. The Fund is intended for short-term trading and is not designed for long-term investment. Investors who hold shares for periods longer than a single trading day may experience returns that are substantially different from the Fund’s stated objective. The Fund requires active monitoring and management.
Compounding and Market Volatility Risk. The Fund has a daily leveraged investment objective, and the Fund’s performance for periods greater than a trading day will be the result of each day’s returns compounded over the period, which is very likely to differ from two times (200%) the Target Portfolio’s performance, before fees and expenses. The Fund will lose money if the Target Portfolio’s performance is flat over time, and it is possible that the Fund will lose money even if the Target Portfolio’s market value increases over a period longer than a single day. Due to daily rebalancing and the effects of compounding, the volatility of the Target Portfolio may affect the Fund’s return as much as, or more than, the Target Portfolio’s actual return. The impact of compounding will affect each shareholder differently depending on the period of time an investment in the Fund is held and the volatility of the Target Portfolio during that holding period.
Derivatives Risk. The Fund utilizes derivatives, including swap agreements and options contracts, to achieve its investment objective. Derivatives involve risks different from, and potentially greater than, those associated with direct investments in securities. These risks include increased volatility, imperfect correlation, liquidity constraints, valuation complexity, and the potential for losses exceeding the amount initially invested.
Counterparty Risk. The Fund is subject to counterparty risk through its use of derivatives. If a counterparty to a swap or other derivative instrument fails to meet its contractual obligations, the Fund may experience losses, delays in recovery, or reduced exposure.
Space Investing Risks. The Fund concentrates its exposure in companies involved in the space economy, including satellite communications, launch services, and space-enabled technologies. Companies involved in the design, manufacture, or launch of spacecraft, launch vehicles, or related systems face significant risks associated with launch failures, deployment malfunctions, mission delays, and cost overruns; space launches are inherently complex and costly, and failures may result in total loss of spacecraft or payloads, substantial financial losses, reputational harm, and increased regulatory scrutiny. Space-related businesses often rely on advanced, emerging, or unproven technologies and may be adversely affected by rapid technological change, engineering challenges, or competitors’ development of superior or lower-cost technologies. The space industry is subject to extensive domestic and international regulation, including licensing requirements, export controls, national security restrictions, environmental regulation, and orbital debris mitigation standards; changes in laws or regulatory interpretations may increase compliance costs, delay operations, or limit deployment of space-based systems. Many space-focused companies depend on governmental or quasi-governmental customers and contracts, and reductions in government budgets, policy changes, or contract terminations could materially affect revenues. Space-based operations are exposed to risks from orbital debris, collisions, congestion in Earth’s orbits, and space weather, any of which may damage satellites or spacecraft and result in service disruptions or complete mission failure. Many space-focused companies may have limited operating histories, depend on a narrow set of products or services, or rely on a small number of customers or missions. The Fund may have exposure to foreign issuers, including through ADRs, which can involve political instability, geopolitical tensions, trade restrictions, sanctions, and currency fluctuations that may disrupt supply chains or impair cross-border collaboration. When the Adviser determines there are insufficient Space Companies to meet the Fund’s investment criteria, the Fund may obtain exposure to secondary space technology companies that support or enable space-related activities, which may be less directly exposed to the growth of the space economy and may be more sensitive to broader industry or market risks. The space industry is emerging and may experience higher volatility and uncertainty than more established industries.
Industry Concentration Risk. Because the Fund focuses on a specific theme and industry group, it may be more susceptible to adverse developments affecting that sector than a broadly diversified fund. The Fund will concentrate (i.e., invest 25% or more of its total assets) its investment exposure to companies in the space industry and in industries that develop, deploy, or operate space-related technologies and services.
IPO, SPAC, and De-SPAC Risk. The Fund may invest, including indirectly via derivative instruments, in securities of companies that have recently completed initial public offerings (“IPOs”), special purpose acquisition companies (“SPACs”), or companies that have become publicly traded through business combinations involving SPACs (“de-SPAC transactions”). These securities may be less seasoned, lack a meaningful trading history, have limited public information and research coverage, and involve risks similar to those of venture capital or other private equity investments. Their prices may be volatile, subject to speculative trading, and susceptible to rapid and substantial declines in value. SPACs are shell or blank check companies that raise capital in an IPO for the purpose of completing a business combination with a private operating company; there is no guarantee that a SPAC will complete a business combination or that any completed transaction will be successful. Conflicts of interest may arise among a SPAC’s sponsors, affiliates, officers, directors, or promoters and unaffiliated security holders.
Swap Agreements. The use of swap transactions is a highly specialized activity, which involves investment techniques and risks different from those associated with ordinary portfolio securities transactions. Whether the Fund will be successful in using swap agreements to achieve its investment goal depends on the ability of the Adviser to structure such swap agreements in accordance with the Fund’s investment objective and to identify counterparties for those swap agreements.
Non-Diversification Risk. The Fund is classified as non-diversified, which means it may invest a larger percentage of its assets in a smaller number of issuers. As a result, the Fund’s performance may be more volatile and more sensitive to the performance of individual holdings.
Equity Securities Risk. Investments in equity securities are subject to market risk, including the potential for significant price fluctuations due to company-specific events, broader market conditions, economic developments, and changes in investor sentiment.
Foreign and ADR Risk. To the extent the Fund has exposure to foreign issuers or American Depositary Receipts (ADRs), it may be subject to additional risks, including currency fluctuations, political and economic instability, differing regulatory standards, and reduced liquidity.
Small- and Mid-Capitalization Risk. The Fund may invest in small- and mid-cap companies, which may be more volatile, less liquid, and more sensitive to economic changes than larger companies.
Liquidity Risk. In certain market conditions, the Fund’s investments or derivative instruments may become less liquid, making it difficult to adjust exposure or achieve the desired investment objective. Reduced liquidity may also lead to wider bid-ask spreads for Fund shares.
Rebalancing Risk. The Fund seeks to rebalance its exposure daily to maintain its target leverage. If the Fund is unable to rebalance effectively due to market disruptions, liquidity constraints, or operational issues, its exposure may deviate from its intended objective.
Tracking and Correlation Risk. There is no guarantee that the Fund will achieve a high degree of correlation to 200% of the daily performance of its underlying portfolio. Market volatility, fees, transaction costs, and derivative pricing may cause performance to deviate from expectations.
High Portfolio Turnover Risk. The Fund’s strategy involves frequent trading and daily rebalancing, which may result in high portfolio turnover, increased transaction costs, and potentially higher taxable distributions.
Tax Risk. The Fund intends to qualify for favorable tax treatment as a regulated investment company (RIC), but there is no guarantee it will do so. Distributions may be taxable as ordinary income, capital gains, or a combination of both.
New Fund Risk. The Fund is recently organized and has limited operating history. As a result, there is limited performance history for investors to evaluate.
Market and Economic Risk. The value of the Fund’s investments may decline due to general market conditions, economic trends, geopolitical events, interest rate changes, inflation, or other external factors beyond the control of the Fund.
Brokerage commissions may be charged on trades.
Distributed by Foreside Fund Services, LLC.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/623c9438-6e10-4373-bc05-a6ae8c312daf
SpaceX's blockbuster IPO has some analysts warning that years of aggressive growth may be already priced in. Retail investor enthusiasm could become a risk if SpaceX misses revenue or earnings expectations.
A general view of a SpaceX facility on the day of the company’s initial public offering (IPO), in Starbase, Texas, U.S., June 12, 2026. REUTERS/Gabriel V. Cardenas Purchase Licensing Rights, opens new tab
June 15 (Reuters) - Elon Musk said on Sunday that his rocket company, SpaceX (SPCX.O), opens new tab, could bring in $1 trillion in revenue by 2030, making the statement two days after the company went public, valuing it at over $2 trillion.
"And I would be surprised if revenue is not greater than $1T in 2031," he wrote on his social media platform X, replying to journalist and financial commentator Jon Erlichman.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
SpaceX on Friday became the sixth-largest U.S. firm, cementing Musk's status as the world's first trillionaire.
However, the company still makes far less money than similarly valued tech giants like Broadcom (AVGO.O), opens new tab and Amazon.com (AMZN.O), opens new tab.
In 2025, SpaceX's revenue jumped to $18.67 billion from $14.02 billion a year earlier, but the company swung to a net loss of $4.94 billion from a profit of $791 million.
Some Wall Street analysts are cautious about the company's growth.
Goldman had estimated that SpaceX's revenue would exceed $470 billion in 2030, while Morgan Stanley projected it would reach nearly $330 billion, according to a Wall Street Journal report from earlier this month.
Reporting by Shivani Tanna in Bengaluru; Editing by Nivedita Bhattacharjee
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Meta Platforms remains a top AI growth story, now trading at only 18x forward P/E after a 14% YTD decline. I reiterate a Strong Buy rating, viewing the recent sell-off as overblown given META's consistent top and bottom-line outperformance. META's robust historical earnings, double beats, and exposure to multi-year AI, data center, and digital ad growth are undervalued by the market.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of UBER either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Microsoft CEO Satya Nadella compared AI's impact to the problems globalization first caused. George Chan/Getty Images AI models are hoovering up corporate knowledge, and that's leaving one big loser, says Satya Nadella.
In an article posted on X on Sunday, the Microsoft CEO warned of a future in which a handful of AI providers capture most economic value while industries lose ownership of their knowledge.
"The last thing any of us want is a world where every company across every sector is ceding value to a few models that eat everything they see," Nadella wrote. "There is no societal permission for an AI future that hollows out entire industries."
Nadella compared the AI era to globalization, warning against repeating that dynamic.
"Think about what happened in the first phase of globalization, where entire industrial economies were hollowed out by outsourcing," he wrote. "The GDP numbers looked fine on the surface, but the displacement was real and the consequences are still being felt."
Instead, he advocated for a broad AI ecosystem in which companies keep control of their learning systems, which he said would enable innovation and retain employee expertise.
Nadella's post echoed concerns other Big Tech CEOs have been raising this year.
In a February podcast, Snowflake CEO Sridhar Ramaswamy said that the biggest software companies are at risk of being reduced to mere data sources.
"The big model makers want to create a world in which all of the data for all of the enterprises is easily available to them," Ramaswamy said. "Everything else, the world, is just a dumb data pipe that feeds into that big brain."
Ramaswamy added that Snowflake needs to operate with a "fear" that people would stop using AI agents developed by software companies and instead want an all-inclusive agent that has data from Snowflake and everywhere else.
In a January LinkedIn post, Box CEO Aaron Levie said that AI models can perform high-level knowledge work across nearly every profession, from law to strategy and scientific research.
"The question that we will have to wrestle with is, in a world where everyone has access to the same expert intelligence, how does a company differentiate?" Levie wrote. He said that context would be the answer.
Read next
Shubhangi Goel You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Tyra Banks is suing Netflix. Manny Carabel/Getty Images Tyra Banks, a model and the creator of the reality TV show "America's Next Top Model," is suing Netflix.
In a 65-page lawsuit filed on Saturday, Banks' attorneys accused the streaming service of falsely portraying her in the three-part docuseries, "Reality Check: Inside America's Next Top Model."
The three-part documentary was released in February. It charted the meteoric rise of the long-running modeling reality show from its early days to its immense cultural impact. It included an interview with Banks and her onetime collaborators, like creative director Jay Manuel and runway coach J. Alexander, and featured at least 10 contestants.
Banks' attorneys filed a lawsuit against Netflix, the producers of the show Everwonder Studio, and directors Mor Loushy and Daniel Sivan. They said the docuseries cut out parts of her interview in which they said she took responsibility for some of the show's controversies.
"Of the hours of answers Ms. Banks provided, the producers used only about sixteen minutes," her team wrote in the lawsuit. "The producers used what could be stripped of context and reassembled to support a false and defamatory narrative unrelated to what she actually expressed."
The team said that Banks gave the documentary producers a three-and-a-half-hour interview and did not limit the interviewer's questions.
"The accountability Ms. Banks took ended up on the cutting room floor. It was there, but viewers were never given the opportunity to see it," they added.
Her attorneys said that the producers created a false narrative through "selective editing, deliberate omission, and surgical manipulation of continuous footage."
One of the major complaints listed in the lawsuit was that the producers interviewed season two contestant Shandi Sullivan, who told them she had viewed an incident that happened on set as sexual assault.
Banks said the producers did not disclose Sullivan's account to her before the interview, and they selectively edited her responses to make it appear that she was not willing to take accountability for the incident.
The lawsuit said that before taking legal action, the team had asked Netflix for unedited footage of Banks' interview, but Netflix denied the request. It added that Netflix did not give Banks the opportunity to respond to any allegations from other participants.
In the lawsuit, Banks' team sought damages and the removal of her face from the album cover of a 26-track soundtrack for the documentary.
Netflix, which has not yet filed a response to the lawsuit, declined to comment.
Read next
Aditi Bharade You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Item 1 of 2 A Walmart sign at its booth during the China International Supply Chain Expo in Beijing, China July 16, 2025. REUTERS/Florence Lo
[1/2]A Walmart sign at its booth during the China International Supply Chain Expo in Beijing, China July 16, 2025. REUTERS/Florence Lo Purchase Licensing Rights, opens new tab
CompaniesBEIJING, June 15 (Reuters) - China's market regulator has ordered strict measures by Walmart supermarket chain Sam's Club to eliminate food safety risks throughout its supply chain and safeguard public dietary safety, the regulator said.
The admonition comes amid a push to expand in China during which Sam's Club racked up double-digit growth in transactions last year as new openings boosted its tally of membership-only stores to 63 nationwide, its website shows.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
The action followed a meeting with an executive of the U.S. retailer to discuss recently detected food safety issues, the State Administration for Market Regulation said in a notice on Monday, without giving the date of the meeting.
Walmart's China office did not immediately respond to a request for comment.
"We will regularly report rectification progress to the regulatory authorities and proactively accept supervision," Sam's Club said in an apology, according to a state-backed media outlet, the Paper.
The chain has set up a special task force led by management to remedy matters, along with supply chain inspections, while offering assurances of strict compliance with rules and optimal product quality control, it added.
Reporting by Liz Lee and Beijing newsroom; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles., opens new tab
An empty Starbucks store in Seoul, South Korea, May 26, 2026. REUTERS/Kim Hong-Ji Purchase Licensing Rights, opens new tab
SummaryCompaniesStarbucks Korea to close all stores June 22 for staff training after marketing backlashControversy stemmed from 'Tank Day' promotion coinciding with Gwangju Uprising anniversaryStarbucks Korea remains market leader with over 2,000 storesSEOUL, June 15 (Reuters) - Starbucks Korea will shut all stores in the country at 3 p.m. on June 22 for staff training on historical awareness and social sensitivity, the operator Shinsegae Group (004170.KS), opens new tab said on Monday, following public backlash over a marketing campaign.
The coffee chain faced widespread criticism and suffered a "very significant" drop in sales after last month's campaign that evoked a brutal 1980 military crackdown on pro-democracy protesters.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
Shinsegae's affiliate E-Mart (139480.KS), opens new tab owns Starbucks Korea, which launched its 'Tank Day' tumbler promotion on the anniversary of the May 18 Gwangju Uprising, when the military government deployed troops and tanks to suppress pro-democracy demonstrations.
Starbucks Korea headquarters staff and executives from Shinsegae's E-Mart division will undergo the same training on June 17 at the group's in-house training centre, while Shinsegae Chairman Chung Yong-jin and affiliate CEOs will attend a separate session on June 24, the group said.
Shinsegae said the move reflected how seriously it viewed the recent marketing controversy and its commitment to preventing a recurrence. Chung previously apologised publicly over the controversy.
The history awareness lecture, led by a history professor from Sungkyunkwan University, will review the major events in South Korea's modern and contemporary history since the 1950s and discuss how they should be understood, it said.
A separate social sensitivity training, conducted by a sociology professor at the same university, will look at how companies should consider social issues such as history, labour, gender and human rights in marketing and other corporate activities, the company said.
The company said it would be the first nationwide early closure of Starbucks Korea stores since the chain opened in the country in 1999.
Starbucks Korea also plans to overhaul marketing approval procedures, including introducing a social-sensitivity checklist covering history, commemorative dates, politics, disasters, military issues, gender, violence and hate expressions, Shinsegae said.
Starbucks Korea had more than 2,000 stores in the country as of end-2024 according to its annual impact report. It is the country's No. 1 coffee chain in terms of customer payments, according to data firm WISEAPP.
Reporting by Joyce Lee, Jack Kim and Kyu-seok Shim Editing by Ed Davies
Our Standards: The Thomson Reuters Trust Principles., opens new tab
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications.
As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabilities, dPCR is gaining adoption across a growing range of applications traditionally served by qPCR technologies. QIAGEN is expanding the QIAcuity ecosystem with new gene expression solutions, workflow automation and analysis capabilities designed to support broader adoption of digital PCR across research and biopharma applications.
"Gene expression represents one of the largest application areas in molecular biology and a significant opportunity for digital PCR," said Thierry Bernard, CEO of QIAGEN. "By expanding the QIAcuity ecosystem with new assays, enhanced multiplexing capabilities and workflow solutions, we are helping customers apply digital PCR to a broader range of research and biopharma applications."
The latest additions to the QIAcuity portfolio include:
New gene expression solutions for dPCR: QIAGEN plans to expand its portfolio later in 2026 with new QIAcuity Gene Expression Assays designed to support gene expression analysis across human, mouse and rat research applications. The company also plans to introduce the new QIAcuity OneStep High Multiplex Probe PCR Kit, enabling analysis of up to 12 RNA targets in a single reaction and helping researchers generate richer biological insights while reducing sample consumption, hands-on time and workflow complexity. These additions complement QIAGEN's GeneGlobe platform, providing access to more than 10 million predesigned assays as well as custom assay design capabilities for specialized research needs. Expanded Cell and Gene Therapy quality control portfolio: Building on its established portfolio of dPCR solutions for Cell and Gene Therapy applications, QIAGEN is expanding its residual DNA testing offering to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero and Mouse. The portfolio also includes the recently launched QIAcuity HEK293 resDNA Sizing Kit, which enables precise measurement of both host-cell DNA concentration and fragment size distribution to support biopharmaceutical development and manufacturing workflows. Enhanced automated analysis and reporting with QIAcuity Software 3.5: Scheduled for release later this month, QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities that enable users to define analysis and reporting parameters before a run begins. The software helps laboratories automate and standardize data interpretation and reporting through predefined analysis and reporting templates. By automatically applying analysis parameters and generating reports after run completion, laboratories can reduce manual review steps while improving traceability, consistency and operational efficiency, particularly in larger-scale and regulated workflows. Expanded laboratory automation through Hamilton integration: In addition to the automated analysis and reporting capabilities introduced with QIAcuity Software 3.5, customers can build on QIAGEN's collaboration with Hamilton to automate QIAcuity dPCR nanoplate setup and handling workflows, including sample preparation, nanoplate filling and sealing. Integration with robotic systems enables fully automated workflows from assay setup through data analysis, helping high-throughput laboratories increase productivity while minimizing risks associated with manual handling. QIAcuity adoption continues to grow across academia, biopharma and clinical research, with over 3,200 cumulative placements worldwide since launch. More than 400 customers now operate multiple QIAcuity instruments, while over 1,100 scientific publications reference the platform. The continued expansion of the QIAcuity ecosystem reflects QIAGEN's strategy to support customers throughout the transition from qPCR to dPCR and toward increasingly scalable, automated and standardized dPCR workflows.
Additional details on QIAGEN's QIAcuity dPCR strategy, technology roadmap and growth opportunities will be discussed during the upcoming QIAcuity Deep Dive event on Monday, June 15, 2026. The event will be webcast and available to investors, analysts and other interested stakeholders. More information is available at https://corporate.qiagen.com/English/investor-relations/events-and-presentations/QIAGEN-Deep-Dive--QIAcuity-digital-PCR/default.aspx.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Oshkosh Defense Highlights Proven, Adaptable Tactical Mobility Solutions for Europe at Eurosatory 2026 As European and allied forces accelerate modernization efforts in response to evolving operational threats, Oshkosh Defense LLC, an Oshkosh Corporation [NYSE: OSK] business, will showcase proven tactical mobility solutions at Eurosatory 2026 designed to support interoperability, distributed operations and future battlefield requirements, without the risk and long development timelines of entirely new vehicle programs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614504023/en/
Oshkosh Defense Hybrid Electric Joint Light Tactical Vehicle (eJLTV).
For decades, Oshkosh Defense has supported allied military forces with heavy, medium and light tactical vehicle platforms designed to operate across coalition environments. Today, as NATO and European partners prioritize readiness, sustainment resilience and operational flexibility, Oshkosh Defense continues to evolve its proven platforms to meet emerging mission requirements. At Eurosatory 2026, Oshkosh Defense will feature its hybrid electric Joint Light Tactical Vehicle (eJLTV), an advanced capability demonstrator built on the combat-proven JLTV platform currently fielded by the United States and allied nations worldwide. With more than 24,000 JLTVs produced, the platform provides a mature, interoperable foundation capable of adapting to future operational requirements while maintaining commonality across coalition forces. The eJLTV demonstrates how allied forces can modernize tactical mobility capabilities while reducing transition risk, leveraging existing sustainment infrastructure and preserving operational familiarity for deployed forces. The platform integrates hybrid electric capability, onboard exportable power generation, silent watch and silent drive functionality to support distributed operations, next-generation battlefield systems and evolving operational energy requirements.
By building on a fielded and combat-proven platform, Oshkosh Defense offers allied customers a scalable path toward future capability integration without sacrificing reliability, survivability or interoperability. The JLTV platform also creates opportunities for localized sustainment, long-term fleet support and regional operational integration aligned with allied modernization priorities.
“European and allied forces are modernizing under real operational pressure, and they also need solutions that can be fielded, sustained and integrated quickly,” said Pat Williams, Chief Programs Officer at Oshkosh Defense. “The eJLTV demonstrates how Oshkosh Defense can evolve a combat-proven platform to support future power, interoperability and distributed operational requirements without forcing customers to accept the risk and timelines associated with entirely new vehicle programs.”
Attendees can experience the eJLTV and learn more about Oshkosh Defense’s portfolio of advanced tactical mobility solutions and technologies at Eurosatory 2026 in Booth A320 in the USA Pavilion.
About Oshkosh Defense
Oshkosh Defense, an Oshkosh Corporation business [NYSE: OSK], delivers adaptable, connected, and survivable systems critical to the modernization and readiness of the U.S. and its allied forces. As a trusted mobility integrator, Oshkosh brings advanced vehicles, intelligent systems, and mission-critical technologies together into unified solutions built for evolving operational demands. Combining defense expertise with commercial scale, Oshkosh accelerates innovation from development through deployment. And because the mission does not end at fielding, Oshkosh provides global sustainment, lifecycle support, and aftermarket solutions that keep fleets ready while advancing the future of defense mobility.
Learn more at OshkoshDefense.com.
About Oshkosh Corporation
At Oshkosh (NYSE: OSK), we make innovative, purpose-built vehicles and equipment to help everyday heroes advance communities around the world. Headquartered in Wisconsin, Oshkosh Corporation employs over 18,000 team members worldwide, all united behind a common purpose: to make a difference in people’s lives. Oshkosh products can be found in more than 150 countries under the brands of JLG®, Pierce®, MAXIMETAL, Oshkosh® S-Series™, McNeilus®, IMT®, Jerr-Dan®, Frontline™ Communications, Oshkosh® Airport Products, Oshkosh AeroTech™, Oshkosh® Defense and Pratt Miller. For more information, visit oshkoshcorp.com.
Forward Looking Statements
This news release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including, without limitation, statements regarding the Company’s future financial position, business strategy, targets, projected sales, costs, earnings, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations, are forward-looking statements. When used in this news release, words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project” or “plan” or the negative thereof or variations thereon or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, assumptions, and other factors, some of which are beyond the Company’s control, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include risks related to the Company’s ability to successfully execute on its strategic road map and meet its long-term financial goals. Additional information concerning these and other factors is contained in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this news release. The Company assumes no obligation, and disclaims any obligation, to update information contained in this news release. Investors should be aware that the Company may not update such information until the Company’s next quarterly earnings conference call, if at all.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260614504023/en/
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (≥12 years of age) with fibrodysplasia ossificans progressiva (FOP). Results were shared in a late-breaking rapid-fire presentation at ENDO 2026, the Endocrine Society’s annual meeting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614539468/en/
Results from Cohort 1 of the PROGRESS study demonstrated a consistent treatment effect across measures of disease activity and durability through Week 48. During the open-label extension, no new HO lesions were observed among patients who continued to receive zilurgisertib or among placebo-treated patients who crossed over to active treatment at Week 24.
"The findings presented at ENDO represent an important milestone for the zilurgisertib program and further strengthen the growing body of clinical evidence supporting its potential as a treatment for FOP," said Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-Stage Development at Incyte.
"People living with FOP and their families urgently need additional treatment options," said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. "These results reinforce our confidence in the potential of zilurgisertib and our commitment to working with Incyte to bring this important program forward as we prepare for potential commercialization and support the FOP community."
Cohort 1 of the PROGRESS study evaluated zilurgisertib 100 mg once-daily in 63 adolescents and adults (≥12 years of age) with FOP. Patients were randomized 1:1 to receive zilurgisertib (n=32) or placebo (n=31) during a 24-week, placebo-controlled, double-blind period, followed by an open-label extension period. Baseline demographics and disease characteristics were generally balanced between treatment groups, with a mean age of approximately 21 years and evidence of recent disease activity prior to enrollment. A total of 61 patients had 48-week whole-body CT scan data available at the time of the open-label extension analysis.
Key efficacy findings included:
Fewer patients receiving zilurgisertib developed new HO lesions at Week 24, with an 81% reduction versus placebo (p=0.0986). 99.9% reduction in total volume of new HO lesions in patients receiving zilurgisertib versus placebo at Week 24 (nominal p-value<0.0001). Reduction in total existing HO lesion volume compared with an increase observed in placebo-treated patients at Week 24 (nominal p-value=0.004). Among patients receiving zilurgisertib, no new HO lesions were observed and total HO lesion volume continued to decrease from Week 24 to Week 48. Among patients who crossed over from placebo to zilurgisertib, no new HO lesions were observed and total HO lesion volume decreased from Week 24 to Week 48. Key Efficacy Findings (Week 24 Placebo-Controlled Period and Week 48 Crossover)
Endpoint
Zilurgisertib (ZGB)
(n=32)
Week 24
Placebo
(n=31)
Week 24
Key Finding
Open-Label Extension
Week 48
Number (%) of patients who developed new HO lesions
1 (3.1)
5 (16.7)
81% reduction vs placebo
No patients with new HO lesions observed at Week 48 (n=61)
Zilurgisertib was generally well-tolerated during the 24-week placebo-controlled period of the study. Data showed:
Most adverse events were mild or moderate in severity. No adverse events led to treatment discontinuation or dose reduction. Serious adverse events and Grade ≥3 adverse events occurred at low rates in both treatment groups. The most commonly reported adverse events among patients receiving zilurgisertib were FOP flare-up or aching/pain due to FOP (25%), headache (21.9%), upper respiratory tract infection (21.9%), arthralgia (18.8%), epistaxis (12.5%), and nausea (12.5%). The full abstract is available on the Endocrine Society’s ENDO 2026 website. Detailed analyses are also posted on the Publications & Presentations section of Mirum’s website.
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zilurgisertib for the treatment of FOP in patients 12 years of age and older and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date for zilurgisertib is September 26, 2026.
About Zilurgisertib
Zilurgisertib is an investigational, oral, small molecule, activin receptor-like kinase 2 (ALK2) inhibitor in development for the treatment of Fibrodysplasia Ossificans Progressiva (FOP). Zilurgisertib is designed to inhibit the ALK2 receptor, which is abnormally active in most patients with FOP and leads to bone formation in soft tissues, a process known as heterotopic ossification (HO). FOP is an ultra-rare genetic disease that affects approximately 300 patients in the U.S. and 900 worldwide, with diagnosis typically occurring in early childhood. Zilurgisertib was evaluated in the PROGRESS pivotal Phase 2 study, which formed the basis of a new drug application (NDA). The FDA has accepted the NDA for zilurgisertib in FOP under Priority Review with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2026.
Mirum Pharmaceuticals, Inc. licensed zilurgisertib from Incyte for worldwide development and commercialization.
About the PROGRESS Study
PROGRESS is a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the efficacy and safety of zilurgisertib in patients with fibrodysplasia ossificans progressiva (FOP). PROGRESS Cohort 1 enrolled patients 12 years of age and older who were randomized 1:1 to receive zilurgisertib 100 mg once daily or placebo during a 24-week double-blind treatment period, followed by an open-label extension. Additional PROGRESS cohorts will evaluate the efficacy and safety of zilurgisertib in patients ages 6 to <12 years of age (Cohort 2) and in patients ages 2 to <12 years of age (Cohort 3).
The primary endpoint of the study is the proportion of Cohort 1 patients with new heterotopic ossification (HO) lesions at Week 24 as assessed by whole-body CT scan data. Key secondary endpoints include the number and total volume of new HO lesions, changes in total HO lesion volume and flare activity through Week 24.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.
About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.
To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.
Mirum Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the Company’s planned participation at a scientific congress, Mirum’s continued advancement of zilurgisertib with Incyte, the likelihood of a FDA approval pathway for zilurgisertib and the potential benefit of zilurgisertib in real world settings versus scientific presentations of data. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expected,” “will,” “could,” “would,” “guidance,” “potential,” “continue” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Annual Report for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 25, 2026, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Incyte Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the presentation of data from the PROGRESS study; the potential for zilurgisertib to become a treatment option for people living with FOP; expectations regarding ongoing and future clinical trials for zilurgisertib, including the timing of such trials; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the efficacy or safety of Incyte’s and its partners’ products; the ability of Incyte and its partners to achieve commercial success for their marketed products and product candidates, if approved; Incyte’s and its partners’ ability to obtain and maintain protection of intellectual property for their products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s and its partners’ products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025, and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.
Mirum and the Mirum logo are trademarks of Mirum Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260614539468/en/
Analyst’s Disclosure: I/we have a beneficial long position in the shares of LITE, MRVL, NVDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
ComEd crews have nearly completed the restoration of power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With 99% of affected customers now restored, crews are in the final stages of repairs and remain committed to completing service restoration for all remaining customers.
Multiple bands of severe weather moved through ComEd's northern Illinois service territory on Wednesday and Thursday, bringing intense rain, frequent lightning, and high wind gusts — with speeds reaching roughly 80 mph at peak — causing significant damage to ComEd's infrastructure and resulting in widespread outages across the service territory. At least two tornadoes were confirmed on Thursday, including one in Streator, Illinois, approximately 100 miles southwest of Chicago, and another near Dwight, Illinois, about 80 miles southwest of Chicago, with additional damage assessments ongoing.
Large trees fell across equipment and blocked access to neighborhoods with restoration needs, and hundreds of utility poles were broken and had to be completely replaced. That type of work is complex and takes more time to do safely, even with crews working around the clock. In total, crews replaced nearly 500 poles and used more than 295,000 feet of cable wire during the restoration effort.
Across the two days of severe weather, more than 674,600 ComEd customers experienced outages. Late Saturday evening, isolated thunderstorms produced localized strong wind gusts that caused additional tree and limb damage, resulting in an additional 6,425 outages.
"Our crews have worked tirelessly — around the clock and under challenging conditions — to safely restore power to our customers, and their dedication throughout this storm event has been extraordinary," said David Perez, executive vice president and COO of ComEd. "We are incredibly grateful for their hard work and commitment over the duration of this event. We also want to sincerely thank our customers for their patience and understanding as we worked through the most significant storm damage our service territory has experienced since the 2020 Derecho. We will not rest until the final customers are restored."
More than 3,000 ComEd employees and 2,200 contractors were mobilized during the peak of the response, supported by roughly 400 mutual assistance personnel who arrived Friday to bolster ComEd staff and contractors in their restoration efforts.
Public Safety Reminders
Public safety remains paramount, and ComEd encourages customers to take the following precautions:
If a downed power line is spotted, please immediately call ComEd at 1-800-EDISON1 (1-800-334-7661). Spanish-speaking customers should call 1-800-95-LUCES (1-800-955-8237). Never approach a downed power line. Always assume a power line is energized and extremely dangerous. In the event of an outage, do not approach ComEd crews working to restore power to ask about restoration times. Crews may be working on live electrical equipment, and the perimeter of the work zone may be hazardous. ComEd urges customers to contact the company immediately if they experience a power outage. Customers can text OUT to 26633 (COMED) to report an outage and receive restoration information and can follow the company on X @ComEd or on Facebook at Facebook.com/ComEd. Customers can also call 1-800-EDISON1 (1-800-334-7661), or report outages via the website at ComEd.com/report. Spanish-speaking customers should call 1-800-95-LUCES (1-800-955-8237).
With ComEd’s Outage Tracker, customers can report outages, check estimated time of restoration, view crew status updates, and explore our outage map. Visit ComEd.com/OutageTracker.
ComEd’s mobile app for iPhone and Android® smart phones gives customers the ability to report power outages and manage their accounts; download the app at ComEd.com/app.
ComEd is a unit of Chicago-based Exelon Corporation (NASDAQ: EXC), a Fortune 200 company and one of the nation’s largest utility companies, serving nearly 11 million electricity and natural gas customers. ComEd powers the lives of more than 4 million customers across northern Illinois, or 70 percent of the state’s population. For more information, visit ComEd.com, and connect with the company on Facebook, Instagram, LinkedIn, X and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260614495118/en/
Dublin, Ireland and Heppenheim, Germany--(Newsfile Corp. - June 15, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the launch of its innovative acne cream Winlevi® (clascoterone 1% cream) in Austria and Germany by its commercial partner InfectoPharm Arzneimittel und Consilium GmbH (“InfectoPharm”). Winlevi® is available in both countries since June 1. Cosmo is the exclusive manufacturer of the product.
Formal regulatory approval for Winlevi® in the EU was granted by the European Commission in October 2025. Since then, Cosmo has been working at full speed with its commercial partners to prepare for launch of the compound across 20 European markets.
Winlevi® is the first topical acne therapy in more than 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, is the first commercially available topical androgen-receptor inhibitor acting locally in the sebaceous glands to reduce sebum production and inflammation without systemic anti-androgen effects, supporting safe use in both males and females.
Giovanni Di Napoli, CEO of Cosmo, commented: “Our valued partners are in full swing with the launch of Winlevi® in various European markets. We are delighted with the success of the launches in Austria and Germany by InfectoPharm. Our innovative acne treatment is now available to an even greater number of patients.”
Phillipp Zöller, CEO of InfectoPharm, added: “With clascoterone, we are finally closing a long-standing therapeutic gap in acne treatment by offering dermatologists a precise and well tolerated targeted therapy. We are delighted that, as a partner of Cosmo, we will also be launching Winlevi® in Italy in September.”
As per today, Winlevi® has already been approved in the United States, Canada, Australia, the United Kingdom, New Zealand, Jordan, Singapore, Malaysia, Philippines, Brazil, Mexico, South Korea, Kuwait, Egypt, Oman, and the European Union. Additional registrations are being processed as Cosmo and its partners continue to increase the global commercial availability of this innovative acne treatment.
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose – Building Health Confidence – our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit www.cosmohealthconfidence.com.
About InfectoPharm
InfectoPharm Arzneimittel und Consilium GmbH specializes in the initial and further development of pharmaceuticals. Over the last 35 years, this family-owned German company has established itself as a groundbreaking pioneer in the industry. The portfolio currently comprises about 140 preparations – including numerous innovations in the fields of pediatrics, infectious diseases, pulmonology, dermatology, allergology, and otolaryngology. The InfectoPharm Greoup owns branches in Austria, Italy, the United Kingdom, France and Poland, as well as three strategically complementary subsidiaries in Germany: Pädia GmbH with its distinct pediatric OTC portfolio, and Beyvers GmbH as an internationally known full-service supplier for pharmaceuticals and cosmetics. InfectoPharm Digital Health GmbH finally contributes with a well-established tinnitus app as a modern health solution. The group has more than 470 employees and posts an annual turnover of approximately 330 million euros (2025), with an average growth rate of 10 percent. For more information, please visit www.infectopharm.com/.
Financial Calendar
Half-Year 2026 Results and Report 23 July 2026
Attachments
PDF - English
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301472
Source: Cosmo Pharmaceuticals N.V.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
AV Introduces TOM 50 RE, a Backpackable UGV for Rapid Reconnaissance and Explosive Ordnance Disposal AeroVironment, Inc. (“AV”), a global leader in autonomous systems, today announced the launch of TOM 50 RE, a compact, backpackable uncrewed ground vehicle (UGV) developed by its wholly owned subsidiary Telerob.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615133056/en/
AV’s TOM 50 RE backpackable UGV delivers rapid reconnaissance, explosive ordnance disposal, and autonomous mapping capabilities for dismounted forces operating in contested environments. (Photo: AV)
Designed for mobile exploration, mission-accompanying reconnaissance, explosive threat disposal, and operational support, TOM 50 RE enables dismounted forces, explosive ordnance disposal (EOD) teams, and special operations units—including SWAT—to rapidly deploy robotic capability wherever the mission demands.
The announcement was made at Eurosatory 2026, a global event for defence and security held in Paris.
“The introduction of TOM 50 RE reflects AV’s commitment to delivering robotic systems that directly address the realities of modern ground combat and explosive threat environments,” said Wahid Nawabi, Chairman, President, and Chief Executive Officer of AV. “Today’s operators need systems that move with them, adapt to multiple missions, and provide immediate intelligence while reducing risk to human life. TOM 50 RE delivers that capability in a highly portable form factor built for the tactical edge.”
Weighing less than 10 kilograms (22 pounds) and compact enough to be carried by a single operator, TOM 50 RE enables rapid deployment in confined and complex terrain, while its tracked design, stair-climbing flipper system, and dedicated mobility attachments allow it to overcome obstacles, navigate stairs and uneven terrain, and operate inside structures, delivering up to five hours of endurance and supporting payloads of up to five kilograms without compromising mobility.
With state-of-the-art onboard simultaneous localization and mapping (SLAM) capability, TOM 50 RE autonomously generates detailed maps of interior spaces, including multi-level buildings and global positioning system (GPS)-denied environments such as underground structures and dense urban terrain. Operators can identify and record points of interest directly within the digital map and export mission data immediately following operations, accelerating intelligence exploitation, supporting informed decision-making, and enabling more effective follow-on planning.
Equipped with four integrated high-resolution wide-angle cameras with infrared capability, TOM 50 RE delivers persistent 360-degree situational awareness in day, night, and degraded visual environments. Its advanced internet protocol (IP)-mesh radio architecture provides secure, resilient communications while enabling the system to function as a mobile repeater, extending connectivity for forces operating deep inside structures or complex terrain.
Its modular architecture, enabled by the Mission Module Interface (MMI) or an adapter supporting Telerob’s Universal Component Interface (UCI), allows operators to integrate mission-specific payloads, including advanced camera systems and disruptors, and tailor the system to evolving operational requirements.
“TOM 50 RE was designed to deliver immediate robotic capability at the point of need, where operators face the greatest uncertainty and risk,” said Florian Gruener, Managing Director of Telerob and Product Line General Manager for Uncrewed Ground Vehicles. “Its ability to rapidly conduct these missions in complex terrain allows forces to gain critical situational awareness, mitigate threats, and make faster, more informed decisions—while keeping personnel out of harm’s way.”
Controlled through AV_Halo™ Command running on the Tomahawk Grip family of systems or the Robo Command Control System, operators can seamlessly manage TOM 50 RE alongside other uncrewed systems, enabling coordinated robotic operations and enhancing situational awareness across the mission.
The Four Missions
For mobile exploration, TOM 50 RE provides immediate situational awareness in unknown or high-risk environments, allowing operators to scout structures, confined spaces, and urban terrain without exposing personnel to danger. In mission-accompanying reconnaissance, the system’s integrated simultaneous localization and mapping (SLAM) capability enables it to navigate multi-story buildings, generate detailed interior maps, and identify and mark hazards or points of interest for follow-on forces. In defusing missions, TOM 50 RE supports the safe neutralization of improvised explosive devices and explosive hazards through modular disruptor and drop-charge payloads, allowing operators to mitigate threats from a safe distance. In its support role, in cooperation with the telemax EVO family of products, the system can serve as a mobile communications relay, extend operational reach, provide additional viewing angles, and enhance coordination between robotic and human elements across distributed teams. TOM 50 RE expands AV’s portfolio of intelligent, mission-ready ground robotic systems supporting defence, security, and public safety forces worldwide.
About AV
AV (NASDAQ: AVAV) is a defence technology leader delivering integrated capabilities across air, land, sea, space, and cyber. The Company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities—built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo™, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. For more information, visit www.avinc.com.
Safe Harbor Statement
Certain statements in this press release may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, and assumptions that involve risks and uncertainties, which could cause actual results to differ materially. Factors that may cause such differences include, but are not limited to, our ability to perform under existing contracts and obtain new ones; regulatory changes; competitor activities; market growth; product development challenges; and general economic conditions. For a more detailed discussion of these risks, please refer to AeroVironment’s filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements as a result of new information or future events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260615133056/en/
Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Verra Mobility Corporation (NASDAQ: VRRM) between February 24, 2026 and May 26, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 4, 2026.
So what: If you purchased Verra Mobility common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Verra Mobility class action, go to https://rosenlegal.com/cases/verra-mobility-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 4, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra's relationship with Avis Budget Group ("Avis"), and in particular obtaining a contract extension with Avis. Further, the Company minimized concerns that major rent-a-cars could replace Verra with in-house solutions or outsourced alternatives. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Verra Mobility class action, go to https://rosenlegal.com/cases/verra-mobility-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vrrm-investors-have-opportunity-to-lead-verra-mobility-corporation-securities-fraud-lawsuit-302799485.html
SummaryOWL is deeply undervalued after a 58% crash.The market is afraid of AI disruption and worse inflows.But OWL's portfolio has expanded from 3 to 8 segments in 4 years, with digital infrastructure now 6% of AUM and strong inflows continuing.I believe OWL will be one of the AI's beneficiaries, not its victim.I think OWL is undervalued, and its business stance is much stronger than it seems. That's why I consider it a once-in-a-decade opportunity. peshkov/iStock via Getty Images
Since I published my latest article about Blackstone (BX), I kept Blue Owl Capital (OWL) on my radar. Because I see a great opportunity in the whole sector. And I suspect that OWL
5.09K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of BX, OWL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The information, opinions, and thoughts included in this article do not constitute an investment recommendation or any form of investment advice.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
On June 12, SpaceX (SPCX +19.17%) completed the largest initial public offering (IPO) in history, raising about $75 billion at a valuation of about $1.75 trillion -- more than double the size of any stock market debut before it. By the closing bell, the stock had jumped 19%, lifting the rocket-and-satellite company's value above $2 trillion.
SpaceX went public in the middle of a wave of artificial intelligence (AI) spending unlike anything the market has seen, with the four biggest technology companies alone on track to pour about $725 billion into capital expenditures (much of it on data centers and chips this year) -- up about 77% from last year. To some investors, a record listing landing on top of all that spending looks like the kind of enthusiasm that shows up near market tops. To others, it's a rational response to seemingly insatiable demand that remains largely unmet.
So, is this the top? Here's a look at both arguments.
Image source: Getty Images.
The bear case Bursts of giant, money-losing IPOs have often clustered near market peaks, and SpaceX fits the profile. The company priced at more than 90 times its 2025 revenue while posting a $4.9 billion net loss for the year -- a loss driven largely by the AI unit, the former xAI, that Elon Musk folded into the company.
Yet demand for the IPO was heavy enough that the offering was oversubscribed several times over, with retail investors alone reportedly submitting more than $70 billion in orders.
The backdrop looks stretched, too.
The S&P 500's cyclically adjusted price-to-earnings ratio sits near 40 -- a level it has touched only once before, during the dot-com bubble.
Then there's the spending. The four biggest AI spenders -- Amazon (AMZN 1.24%), Microsoft, Alphabet (GOOG +0.44%)(GOOGL +0.53%), and Meta Platforms -- are spending so heavily that their free cash flow has plummeted. Indeed, Amazon's trailing free cash flow has fallen about 95%, to $1.2 billion, and its 2026 capital expenditures of about $200 billion look poised to outrun its operating cash flow, turning free cash flow negative for the year. To keep building, the group has leaned heavily on the bond market, and Alphabet recently announced a massive $85 billion equity raise.
Meanwhile, the payoff remains hard to find. A widely cited MIT study found that about 95% of corporate generative-AI pilots have yet to produce a measurable return, and in PwC's latest global survey, 56% of CEOs said they were getting essentially nothing from their AI efforts so far.
The bull case But the other side of the argument starts with a simple observation -- the demand is extraordinary.
"[W]e are compute constrained in the near term," said Alphabet CEO Sundar Pichai during the company's first-quarter 2026 earnings call. "... [O]ur cloud revenue would have been higher if we were able to meet the demand."
In other words, Alphabet is turning away cloud revenue because it can't add capacity fast enough. Behind that comment, Google Cloud revenue grew 63% in the first quarter, and its backlog (contracted business it hasn't yet delivered) nearly doubled sequentially to more than $460 billion. The other big providers are growing quickly as well, with Amazon's AWS accelerating sequentially to a year-over-year growth rate of 28%.
Today's Change
(
0.53
%) $
1.90
Current Price
$
359.67
The bulls also point out that these companies have done this before. The same cloud and data center investments that critics once called reckless have become highly profitable businesses. From that view, spending ahead of demand is how the last technology cycle was won, not a warning sign -- and Goldman Sachs projects AI-related spending will climb toward $1.6 trillion a year by 2031.
So, where does this leave investors?
Both sides of the argument deserve some consideration. The skeptics are right that valuations are rich and that we're still largely waiting to see profits big enough to justify this unprecedented spending cycle. And the optimists are right about demand: backlogs are massive, and they seem to keep climbing.
To me, the honest read is that neither camp has won the argument yet. Which one turns out to be right will come down to the single question neither can answer today -- whether all of that spending eventually produces the profits to justify it.
With all of this said, I believe investors may want to consider allocating some of their portfolio to areas that could benefit if the AI boom continues longer than expected, as well as to more conservatively valued investments, with exposure to sectors likely to be more resilient during a pullback in AI spending.
As excitement builds around a potential SpaceX (SPCX +19.17%) investment, many Alphabet (GOOG +0.44%)(GOOGL +0.53%) shareholders already hold indirect exposure through its stake. Discover why leverage, volatility, and a long‑term mindset matter so much by watching the discussion in the video below.
*This video was published on Jun. 12, 2026.
Lou Whiteman has no position in any of the stocks mentioned. Sanmeet Deo, CFA has positions in Alphabet. Tim Beyers has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet. The Motley Fool has a disclosure policy.
Discover why the latest sell‑offs in MercadoLibre (MELI 1.25%) and Coupang (CPNG 2.49%) could set up compelling long‑term opportunities, despite credit, regulatory, and reinvestment risks. Watch the video below to see how patient investors might benefit.
*This video was published on Jun. 12, 2026.
Danny Vena, CPA has positions in Coupang and MercadoLibre. Karl Thiel has positions in MercadoLibre. Rick Munarriz has positions in MercadoLibre. The Motley Fool has positions in and recommends MercadoLibre. The Motley Fool recommends Coupang. The Motley Fool has a disclosure policy.
SummaryThe Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha between June 5 and June 11.This curated selection aims to provide fresh investment ideas and foster community discussion around under-the-radar equities.Readers are encouraged to engage, share perspectives, and highlight additional overlooked investment opportunities.The series serves as a catalyst for discovering unique stocks that may warrant further research and portfolio consideration. brlozier/iStock via Getty Images
The Undercovered Dozen is a weekly Seeking Alpha editor-curated series highlighting 12 articles on lesser-covered stocks from the previous seven days. We hope this provides ideas and inspires discussion among the community.
Today, we're looking at
2.83K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. The author is an employee of Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
Mika Yamamoto, a member of the Board of Directors at BlackLine (BL +2.86%), disclosed the sale of 3,000 shares of common stock in an open-market transaction on June 5, 2026, according to an SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)3,000Transaction value$85,425.60Post-transaction shares (direct)16,692Post-transaction value (direct ownership)~$475,000Transaction and post-transaction values based on SEC Form 4 reported price ($28.48).
Key questionsHow large was this sale relative to the insider's recent trading history?
This 3,000-share sale is at the lower end of Yamamoto's historical sell trades, which ranged from 3,000 to 5,000 shares, and is consistent with the average sell size of approximately 3,740 shares across three sell events.Does this transaction indicate a shift in liquidity strategy or cadence?
The timing and size of the sale match the established pattern of periodic disposals, with the most recent sale reflecting the reduced remaining direct holdings and not a change in trading frequency.Are there any indirect or derivative holdings remaining after this sale?
No indirect or derivative holdings were disclosed as part of this transaction. The remaining 16,692 shares are held directly, with no outstanding stock options reported.How does the timing of the sale relate to BlackLine's market performance?
The sale occurred after a year in which BlackLine shares declined 48.48% (as of June 5, 2026), and the transaction was executed at around $28.48 per share, near the market close price of $28.66 that day.Company overviewMetricValueMarket capitalization$1.67 billionRevenue (TTM)$716.65 millionNet income (TTM)$26.59 million1-year price change-50.80%* 1-year price change calculated as of June 5, 2026.
Company snapshotBlackLine offers cloud-based software solutions for automating accounting and finance operations, including financial close management, account reconciliations, transaction matching, task management, journal entry, variance analysis, compliance, AR automation, and inter-company workflow tools.It generates revenue through direct sales of subscription-based software and related services, targeting critical finance and accounting functions within enterprises.The company serves a global client base of multinational corporations, large domestic enterprises, and mid-sized businesses across diverse industries.BlackLine operates at scale within the financial automation software market, leveraging a comprehensive cloud platform to streamline complex accounting processes for enterprise clients.
The company's strategy centers on expanding its suite of automation tools to address evolving finance department needs, supporting regulatory compliance and operational efficiency. BlackLine's competitive edge lies in its deep domain expertise and ability to deliver integrated, end-to-end solutions for mission-critical financial workflows.
What this transaction means for investorsBlackLine Board of Directors member Mika Yamamoto’s June 5 sale of company stock came at an interesting time. Shares fell to a 52-week low of $24.70 on May 13, and remained near that low when Yamamoto executed her transaction.
Why Yamamoto sold when the stock was well below its 52-week high of $59.57 is not known, but since she retained 16,692 shares after the disposition, and the transaction was in-line with the size of previous sales, these factors suggest she is not rushing to dispose of her holdings. Consequently, this sale does not appear to raise any red flags for investors.
BlackLine stock is down despite reporting revenue of $183.2 million in the first quarter, an increase of 10% year over year. Investors sold shares in Q1 as part of a broader software sector sell-off sparked by fears that artificial intelligence will take business away from companies such as BlackLine.
However, that does not appear to be the case. Not only did BlackLine experience a sales increase in Q1, it anticipates growth extending into Q2. The company forecasted Q2 revenue in the range of $186 million to $188 million, up from $172 million in 2025.
Hasbro remains a buy as Wizards of the Coast drives recurring, high-margin growth and Magic's momentum proves more durable. Magic's ecosystem expansion, record-setting sales, and robust backlist/Secret Lair growth support a shift from hit-driven to recurring revenue. HAS management's FY2026 guidance appears conservative, leaving room for beat-and-raise upside if Magic demand and Consumer Products rebound.
Lexington, NC , June 14, 2026 (GLOBE NEWSWIRE) -- Sky Aircraft Maintenance (SAM), an FAA-certified Part 145 Repair Station and member of the Atlantic Jet Partners family of companies, is proud to announce that it has been named an authorized Garmin Aviation dealer.
The new dealership allows Sky Aircraft Maintenance to provide factory-authorized Garmin avionics sales, installation, integration, and support for private and business aircraft owners and operators seeking modern flight deck solutions.
Sky Aircraft Maintenance
Garmin has become one of the most trusted names in aviation avionics, offering advanced navigation systems, flight displays, digital autopilots, ADS-B solutions, connected aircraft technologies, and integrated flight deck modernization programs. As an authorized Garmin dealer, Sky Aircraft Maintenance can now support a wide range of Garmin upgrades, from focused avionics improvements to complete cockpit transformations.
One of the most significant opportunities for business aircraft operators is Garmin's G5000 integrated flight deck retrofit program. Available for select aircraft including the Beechjet 400A, Hawker 400XP, and Citation 560XL / Excel / XLS series, the G5000 replaces aging avionics architecture with a modern integrated flight deck featuring touchscreen controllers, advanced navigation capability, digital autopilot integration, wireless cockpit technology, and enhanced situational awareness.
For many operators, a G5000 retrofit provides a practical path to extend the useful life of proven airframes while addressing avionics obsolescence, improving reliability, and enhancing long-term supportability.
In addition to flight deck modernization, Garmin's wireless cockpit technologies help streamline pilot workflow through wireless flight plan transfer, avionics database management, mobile device integration, and connected aircraft capabilities that simplify cockpit operations before, during, and after flight.
"Aircraft owners and operators are looking for solutions that improve capability, reduce pilot workload, and help protect the long-term value of their aircraft," said Christopher Arnett of Sky Aircraft Maintenance. "Garmin continues to lead the industry with products that accomplish those goals, and we're excited to bring those solutions to our customers as an authorized Garmin dealer."
Sky Aircraft Maintenance can now assist customers with:
As a full-service maintenance facility, Sky Aircraft Maintenance can also coordinate Garmin avionics upgrades alongside scheduled inspections, maintenance events, connectivity upgrades, interior refurbishments, and other aircraft services. This approach helps reduce downtime and allows owners to accomplish multiple projects during a single visit.
To celebrate the new Garmin dealership, aircraft owners and operators are encouraged to contact Sky Aircraft Maintenance to learn more about current avionics upgrade opportunities and how they may qualify for 10% off scheduled maintenance when combined with a Garmin avionics upgrade.
To learn more about Garmin avionics solutions available through Sky Aircraft Maintenance, visit: https://atlanticjetpartners.com/garmin-avionics-aircraft-upgrades/
About Sky Aircraft Maintenance
Sky Aircraft Maintenance is an FAA-certified Part 145 Repair Station located in Lexington, North Carolina. SAM provides aircraft maintenance, avionics installation, inspections, connectivity upgrades, interior refurbishments, pre-purchase inspections, and aircraft modernization services for private and business aircraft operators throughout North America.
Sky Aircraft Maintenance Named Authorized Garmin Aviation Dealer
Sky Aircraft Maintenance Named Authorized Garmin Aviation Dealer New Garmin dealership expands avionics modernization capabilities for private and business aircraft ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of POET Technologies Inc. (NASDAQ: POET) between April 1, 2026 and 08:57 AM ET on April 27, 2026, inclusive (the “Class Period”), of the important June 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
SO WHAT: If you purchased POET Technologies securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the POET Technologies class action, go to https://rosenlegal.com/submit-form/?case_id=62524 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 29, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) POET Technologies misrepresented its tax status due to it likely being deemed a passive foreign investment company (or “PFIC”) under U.S. tax laws which, if not properly reported by each U.S. stockholder, would have negative tax implications for those U.S. stockholders; (2) the foregoing tax issue would, if discovered, make POET Technologies a less attractive investment than it would otherwise be, thus threatening POET Technologies’ valuation; (3) Defendant Thomas Mika, despite affirming that he was not violating a non-disclosure agreement, in fact violated a business agreement by speaking about POET Technologies' business agreements in a public interview, thus endangering POET Technologies’ business prospects, and (4) as a result, defendants’ statements about POET Technologies’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the POET Technologies class action, go to https://rosenlegal.com/submit-form/?case_id=62524 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
Dell Stock Surge Boosts Michael Dell's Net Worth By $72 BillionThe ongoing Dell stock surge has pushed its market capitalization to over $256 billion. This surge has helped to push Michael Dell's net worth by $72 billion this year to $213 billion, making him the 6th wealthiest person in the world.
Michael owns about 40% of Dell Technologies. At the same time, he owns DFO Management, an asset management company that manages his wealth and invests in hotels and liquid corporate credit.
Dell shares have jumped this year as the company became a major player in the AI infrastructure industry. That is because it sells items like servers and networking equipment that are used by the biggest hyperscalers.
A report released in May showed that the company was firing on all cylinders. Its revenue jumped by 88% in the first quarter to $43.8 billion. This growth was driven by its infrastructure division, whose revenue soared by 181% to $29 billion. Its servers soared by 757% to $16.1 billion.
Dell's client solutions group made over $14.6 billion in Q1, up by 17% from the same period last year. As a result, the company boosted its forward guidance and continued to return funds to its shareholders. It now expects that its revenue will jump by 50% in Q2 to $45 billion, while its full-year figure will soar by 47% to $169 billion.
Dell stock is also benefiting from a recently-announced $9.7 billion deal with the Department of War. This deal also includes Microsoft (NASDAQ:MSFT) services and is expected to save the government over $422 million.
Dell Valuation Multiples Point to More GainsThe ongoing Dell stock surge may have more room to run based on momentum and the fact that the company is not all that expensive. Data shows that the company has a forward price-to-earnings ratio of 22, slightly lower than the S&P 500 Index average of 23. This is crucial as the company is growing at a faster pace than the broader stock market by far.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Analysts are Bullish on the Sandisk StockDespite the ongoing surge in SNDK stock, analysts remain broadly bullish and expect further upside. In a recent note, analysts at Cantor Fitzgerald boosted their target from $1,800 to $2,900.
Mizuho hiked its target from $1,825 to $2,200, while Bank of America (NYSE:BAC) increased to $2,100. The most optimistic analyst is Mehdi Hosseini of Susquehanna, who hiked his target from $2,000 to $3,250.
Sandisk is Benefiting From the Memory BoomWall Street analysts are optimistic that Sandisk's business will continue growing in the coming years. The average estimate among 19 analysts tracking the company is that its revenue will surge 160% this year to $19.6 billion. They expect it to jump by 121% in the following year to $43.4 billion.
Sandisk's earnings-per-share is also expected to soar from $2.99 in 2025 to $65 this year and $183 in 2026.
Valuation multiples show that the company is not all that overvalued, as it has a forward price-to-earnings ratio of 30, lower than the technology sector median of 33. Its forward PEG ratio has dropped to just 0.09, also lower than the median of 1.42.
SNDK Shares Face Key Risks AheadThe other risk is that the law of supply and demand suggests that companies in the industry will ultimately boost supply to take advantage of the elevated prices. If this happens, an elevated supply will likely lead to higher inventory levels and lower prices.
Technicals also suggests that the Sandisk stock has become highly overbought. The Relative Strength Index has jumped to 81 on the weekly chart, suggesting that a pullback may happen in the coming months.
Image: ShutterStock
Market News and Data brought to you by Benzinga APIs
A view shows Woodside Energy's headquarters in Perth, Australia, April 19, 2025. REUTERS/Christine Chen/File Photo Purchase Licensing Rights, opens new tab
CompaniesJune 15 (Reuters) - Australia's Woodside Energy (WDS.AX), opens new tab said on Monday it was not aware of any proposal involving U.S. energy major Exxon Mobil (XOM.N), opens new tab and was not engaged in discussions regarding a potential transaction, responding to recent media speculation.
The statement follows media reports that Exxon is studying a potential acquisition of the LNG producer as part of efforts to deepen its presence in liquefied natural gas and Asian markets.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
Western Australia Premier Roger Cook said on Sunday the government would oppose any takeover that involved relocating Woodside's headquarters from the state, where it has been based since the 1990s.
Woodside is Australia's leading LNG exporter and recently increased its stake in the Browse project to about 42%, reinforcing its role in future supply growth.
Reporting by Roshan Thomas in Bengaluru; Editing by Tom Hogue
Our Standards: The Thomson Reuters Trust Principles., opens new tab
A $2 million dividend portfolio for retirement sounds like you’ve arrived. For a retired couple living in New York, however, the headline portfolio value tells only part of the story. What ultimately matters is not the income shown on a brokerage statement, but the amount that remains available to spend after taxes and other income-related costs are accounted for.
Federal taxes, New York state taxes, and Medicare income-related surcharges can all reduce the cash available for everyday expenses. The difference between gross portfolio income and spendable income can amount to tens of thousands of dollars per year, particularly for retirees generating substantial investment income. Funding groceries, property taxes, travel, and other retirement goals depends on the after-tax income stream, not the headline yield.
Building a Realistic $2 Million Income Portfolio A common retiree allocation built for cash flow looks like this: 60% in dividend-growth equities, 25% in covered call equity income funds, and 15% in REITs. Anchoring the dividend-growth sleeve with names like Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Procter & Gamble (NYSE:PG) is conventional for a reason. JNJ just approved its 64th consecutive annual dividend increase, raising the quarterly payout 3% to $1.34 per share. PG sits on a 70-year streak of annual increases. The REIT sleeve commonly leans on Realty Income (NYSE:O), which has paid 670 consecutive monthly dividends and yields around 5.4%.
Using realistic category yields, the math comes out like this:
Dividend growth, $1.2 million at ~3.5%: $42,000 in mostly qualified dividends. Covered call income, $500,000 at ~9%: $45,000, largely taxed as ordinary income or return of capital. REITs, $300,000 at ~5.5%: $16,500, taxed as ordinary income with a partial 20% QBI deduction. Gross portfolio income: about $103,500.
The Federal Tax Bite For a married couple filing jointly in 2026, the standard deduction is $32,200. After applying that deduction, the portfolio’s ordinary-income distributions are taxed through the lower federal income tax brackets, resulting in an estimated federal tax bill of roughly $3,000. The qualified dividend portion of the income may remain within the 0% long-term capital gains bracket, allowing those distributions to avoid additional federal tax.
The result is a relatively modest federal tax burden compared with the portfolio’s total income. Even so, retirees should focus on after-tax income rather than gross yield when evaluating how much spending power a portfolio can realistically provide.
New York Adds Its Layer State taxes can have a much larger impact than many investors expect. New York generally taxes dividends, REIT distributions, and covered-call income as ordinary income, without the preferential treatment available under federal law for qualified dividends.
At this income level, a retired couple could face an effective New York state tax rate of roughly 5.5%, producing a state tax bill of approximately $5,700. For residents of New York City, local income taxes can add several thousand dollars more. For an upstate couple, combined federal and state taxes would total roughly $8,700, leaving spendable income near $94,800.
The key takeaway is that the portfolio’s headline income is not the amount available to spend. Federal taxes, state taxes, and other retirement-related costs determine how much of that income ultimately reaches the household budget.
The Geography Premium Move the exact same portfolio across state lines and the result changes meaningfully:
State Estimated Annual Tax Spendable Income New York ~$8,700 ~$94,800 Florida ~$3,000 ~$100,500 Texas ~$3,000 ~$100,500 Nevada ~$3,000 ~$100,500 Tennessee ~$3,000 ~$100,500 New York’s 107.9 cost-of-living index compounds the gap. The same dollar buys less when it lands.
IRMAA: The Hidden Medicare Tax Medicare uses a two-year MAGI lookback. For 2026, the joint-filer IRMAA cliff starts above $218,000. At $103,500 in portfolio income plus typical Social Security, this couple stays comfortably below the first surcharge. Push the portfolio to $200,000 in distributions, though, and a Roth conversion or a strong market year can tip MAGI over the line, adding $81.20 per spouse per month to Part B, plus a Part D add-on.
The Insight You Don’t Want To Miss After-tax yield is the metric that matters. A $90,000 portfolio loaded with qualified dividends from compounders like JNJ and PG can deliver nearly identical spendable cash to a $110,000 portfolio stuffed with ordinary-income distributions. Worse, the high-yield portfolio is more likely to push a retiree into IRMAA and erode principal over time. JNJ’s dividend has grown from $0.95 to $1.34 in roughly six years; Realty Income’s monthly check has crept from $0.27 to $0.2705 over the past five months. Both matter, but they play different roles.
What to Do Calculate after-tax yield, not gross yield. Run each holding through your actual federal and New York brackets before comparing it to alternatives. Put ordinary-income holdings inside tax-advantaged accounts. Covered call funds and REITs belong in IRAs whenever possible. Reserve taxable accounts for qualified-dividend compounders. Model the IRMAA cliff before any large Roth conversion or capital gains event. A single transaction can raise Medicare premiums for an entire year.
